AFFILIATIONS
1 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Songjiang District Central Hospital, Shanghai, China
3 Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
5 Shanghai Songjiang District Central Hospital, Shanghai, China
6 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China
13 Shanghai Tissuebank Biotechnology Co., LTD, Pudong New Area, Shanghai, China
14 Shanghai Tissuebank Biotechnology Co., LTD, Pudong New Area, Shanghai, China
15 Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
16 Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
17 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shanghai, China
18 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
ABSTRACT
Background: TP53 allelic status is an established prognostic marker in myeloid neoplasms (MNs), yet outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) remain heterogeneous in both single-hit and multi-hit subgroups. Concurrently, highly sensitive technologies enable direct assessment of TP53-mutated clonal persistence, thereby offering the potential to refine relapse-risk stratification. We therefore investigated whether TP53 mutation functional characteristics and molecular persistence after allo-HCT provide prognostic information beyond allelic status.
Methods: We conducted a multicenter retrospective study of 154 patients with TP53-mutated MNs undergoing first allo-HCT. Patients with confirmed germline TP53 mutations were excluded. TP53 alterations were classified as single-hit or multi-hit. For patient-level analyses, variants were grouped in the following order of priority: putative loss-of-function (LOF)/truncating (splice-site, nonsense, or frameshift insertion/deletion), classic DNA-binding-domain hotspot mutations (structural hotspot R175, Y220, G245, and R282, contact hotspot R248 and R273), or other mutations. TP53 mutations were detected using digital polymerase chain reaction assays with a limit of detection (LoD) of 0.001%. Measurable residual disease assessed by multiparameter flow cytometry (MFC-MRD) positivity was defined at an LoD of 0.01%. Study endpoints included event-free survival (EFS), and cumulative incidence of relapse (CIR). EFS was calculated from allo-HCT to MFC-MRD positivity, relapse, death from any cause, or the last follow-up, whichever occurred first. Associations with EFS and CIR were evaluated using multivariable Cox and competing-risk models. Incremental prognostic discrimination was assessed with time-dependent area under the curve (AUC) and likelihood ratio test (LRT). The diagnostic performance of TP53-MRD and MFC-MRD was compared using McNemar’s test for sensitivity and specificity.
Results: Allelic status was assignable in 149 patients, of whom 102 (68.5%) had multi-hit alterations. After a median follow-up of 706 days, estimated 3-year EFS and CIR were 38.9% and 46.5%, respectively. Multi-hit disease was associated with lower 3-year EFS (28.5% vs. 56.6%, P = 0.001) and higher 3-year CIR (57.7% vs. 30.2%, P = 0.012) than single-hit disease. Across mutation classes, 3-year EFS and CIR were 25.4% and 75.7% for LOF/truncating mutations, 22.9% and 58.1% for classic hotspot mutations, and 54.0% and 31.3% for other mutations (P=0.003, P=0.001). In multivariable analyses, LOF/truncating mutations versus other mutations remained associated with inferior EFS (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.05-3.88; P = 0.036), and higher CIR (subdistribution HR [sHR], 2.48; 95% CI, 1.16-5.28; P = 0.019), whereas allelic status was not independently prognostic. Removing mutation class from the full model reduced time-dependent AUC for 2-year EFS (0.837 to 0.776; P = 0.012), 3-year EFS (0.868 to 0.807; P = 0.020), and 2-year CIR (0.791 to 0.709; P = 0.017). However, removing allelic status did not materially change discrimination. Further, LRT showed that inclusion of mutation class decreased model fit for OS (LRT χ² = 8.87; P = 0.012) or EFS (χ² = 4.99; P = 0.082) and similarly did not improve the Fine-Gray competing-risk model for relapse (χ² = 6.33, P= 0.042). Finally, we evaluated the clinical relevance of post-transplant molecular persistence. TP53 molecular positivity at 3 months after allo-HCT, but not at 1 month, was associated with subsequent treatment failure. Patients with detectable TP53 mutations at 3 months had significantly inferior EFS (HR, 3.82; 95% CI, 1.77–8.26; P < 0.001) and increased relapse risk (HR, 2.46; 95% CI, 1.07–5.63; P = 0.033). Compared with MFC-MRD, TP53-directed molecular monitoring demonstrated higher sensitivity for relapse prediction (83.9% vs. 48.4%, P = 0.003), higher negative predictive value (85.7% vs. 69.2%, P = 0.004), and superior overall predictive performance (AUC, 0.732 vs. 0.617; P = 0.044).
Conclusions: TP53 mutation class, particularly putative LOF/truncating variants, identifies adverse post-transplant biology not fully captured by allelic status. Incorporating mutation class with post-transplant molecular monitoring may improve relapse-risk stratification after allo-HCT, but independent validation is required before clinical application.